Stockreport

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics, Inc.  (RNAC) 
PDF Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration [Read more]